Letters
Fetal RHD typing
Is fetal RHD typing in all RhD negative women cost effective?
BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39556.499549.80 (Published 24 April 2008) Cite this as: BMJ 2008;336:906- Ala Szczepura, professor, health services research1,
- Gouke Bonsel, professor, evaluation of health care2,
- Christian Krauth, associate professor, health economics and public health 3,
- Leeza Osipenko, senior research fellow1,
- Alexander Haverkamp, research fellow4
- 1Clinical Sciences Institute, Warwick Medical School, University of Warwick
- 2Institute for Health Management and Policy, Department of Prenatal and Reproductive Care, Erasmus Medical Centre, Rotterdam University, Netherlands
- 3Institute for Epidemiology, Social Medicine and Health System Research, Hanover Medical School, Germany
- 4Department of Transfusion Medicine, Georg-August-University, Göttingen, Germany
- ala.szczepura{at}warwick.ac.uk
Finning et al show that non-invasive detection of fetal RHD status can be performed in a high throughput laboratory with high sensitivity.1 The associated editorial suggests that universal fetal genotyping of all RhD negative women is a logical extension that would allow the targeting of antenatal anti-D prophylaxis. But would mass testing be cost effective and, if so, under what conditions? The original …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.